New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
07:03 EDTBDSIBioDelivery Sciences completes enrollment for Phase 3 trial of Clonidine
BioDelivery Sciences has completed enrollment of all patients required for its initial Phase 3 study of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. The trial is a multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with PDN. This is the first of two pivotal trials that would be required for submission of a New Drug Application to the FDA. FDA has granted Fast Track designation for the program.
News For BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
17:12 EDTBDSIBroadfin Capital reports 7.33% passive stake in BioDelivery Sciences
May 14, 2015
19:02 EDTBDSIOn The Fly: After Hours Movers
Subscribe for More Information
16:11 EDTBDSIEndo, BioDelivery announces Phase 3 data for buprenorphine
Subscribe for More Information
May 12, 2015
07:00 EDTBDSIBioDelivery Sciences price target lowered to $12 from $17 at Cantor
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use